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A B S T R A C T   
Background: The tailored immunomodulatory treatment strategy for secondary progressive multiple sclerosis 
(SPMS) depends on disease activity. 
Objective: To assess the real-world situation in monitoring disease activity in SPMS patients and to identify as-
sociations of resulting subgroups with demographics, symptomatology, and therapy 
Methods: This study included 4,263 SPMS patients from the German MS register (GMSR). For the classification 
into ‘active’ and ‘inactive’ according to relapse activity and MRI findings during the year prior to the latest 
clinical visit, we used the following definitions: active - gadolinium enhancing (Gd+)/new T2 lesions or ≥1 
relapse, inactive - neither Gd+/new T2 lesions nor relapses. The active, inactive, and unclassifiable patients were 
compared in terms of clinical data, socio-demographics, symptomatology, healthcare, and DMT. 
Results: Classification was possible for 1,513 (35.5%) SPMS patients, with 467 classified as active and 1,046 as 
inactive. For the classification, MRI data was available for 33.2% of the 4,263 patients. Higher MRI frequencies 
were observed for younger patients (OR 1.22 [1.12,1.33] per 10 years) with short disease duration (OR 1.19 
[1.09, 1.30] per 10 years) (p < 0.001). 
Conclusion: MRI coverage was low, especially in elderly SPMS patients. Roughly one third of the SPMS patients 
presented markers of disease activity in the last year. Overall, the clinical differences (concerning symptom-
atology and care) between patients with active and inactive SPMS were small.   
1. Introduction 
Treatment decisions for secondary progressive multiple sclerosis 
(SPMS) are a challenging area. The majority of disease-modifying 
therapies (DMTs) are only approved for relapsing-remitting disease 
courses (Gehr et al., 2019; Gholamzad et al., 2019; Saleem et al., 2019; 
Tintore et al., 2019). However, more recent approvals have also 
included SPMS patients, albeit only for those with an ‘active’ disease, i.e. 
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those with superimposed relapses (interferon beta, ocrelizumab, cla-
dribine – approved for active relapsing MS) or at least inflammatory 
activity (siponimod – approved for active SPMS) as measured via MRI or 
relapse activity (Faissner and Gold, 2019). Detailed knowledge of the 
frequency and characteristics of active and inactive SPMS is required to 
provide suitable treatment strategies and to allocate the resources 
appropriately; however, the supporting data are lacking (Krieger et al., 
2016). In view of this, we defined two groups, ‘active SPMS’ and 
‘inactive SPMS’, based on both reported MRI data and relapse activity. 
Following this, we investigated whether these two groups differ in terms 
of patient characteristics, symptomatology, disease progression, or DMT 
usage, using a large sample of patients documented in the German MS 
Registry (GMSR). 
2. Methods 
The GMSR was initiated in 2001 under the auspices of the German 
MS Society (DMSG), Bundesverband e.V., to collect nationwide data 
from patients with MS. A detailed description of the methodology is 
provided elsewhere (Ohle et al., 2021) (www.msregister.de/en). In 
brief, the GMSR is aimed at collecting both epidemiological data and 
data related to disease course, healthcare, and the social situation of MS 
patients. The GMSR currently covers 189 centres, with more than 35, 
000 patients and over 160,000 visit datasets recorded across the whole 
of Germany since 2014. 
2.1. Inclusion criteria 
Patients whose most recent visit documentation was dated between 
January 2016 and April 2020 were included in this study (mandatory 
MRI and relapse information were only added to the registry dataset at 
the end of 2015). 
2.2. Definitions of active and inactive SPMS 
Disease activity was classified according to criteria adapted from the 
2013 revisions of the clinical course descriptions of multiple sclerosis 
(Lublin et al., 2014): 
active SPMS: 
MRI: contrast (gadolinium) enhancing (Gd+) lesions and/or new T2 
lesions 
or at least one relapse 
inactive (or ’not active’) SPMS: 
MRI: no Gd+ lesions and no new T2 lesions 
and no relapses 
unclassifiable (or ‘activity indeterminate’) SPMS 
Patients not assessed with MRI and no relapses 
The classification of SPMS patients was assessed either at the last 
recorded visit or, in the case of missing information (e.g. no MRI 
available), within the 12 months prior to the patient’s last recorded visit. 
Lublin et al. recommend an at least annual assessment of disease activity 
by clinical and brain imaging criteria, but also consider longer assess-
ment periods to be appropriate for ‘certain situations’, e.g. subgroups 
with progressive MS. To examine such deviations in our (sub)cohort for 
which the classification of the disease activity was not possible in this 
one-year period due to a lack of clinical visits or conducted MRI, or due 
to the non-occurrence of relapses, the classification was extended in an 
experimental approach to the patient’s recent history of up to four 
additional years. The one-year period (time frame) was then enlarged to 
the last classifiable visit per MS patient in the last five years but never 
prior to the SPMS conversion date (see Supplementary Figure 1) in order 
to see whether information can be gained. 
2.3. Statistical analysis 
The main analyses involved the assessment of actual classifiability 
and the comparison of information of interest at the last visit or at the 
last assessable date and were exploratory in nature. This information 
included the following: gender; age; age at onset of MS; duration of 
disease since first symptoms; time to and since conversion to SPMS; 
symptoms at onset; current symptoms and symptomatic treatment, 
including physiotherapy and disability (as measured using the expanded 
disability status scale [EDSS]); multiple sclerosis severity score (MSSS); 
employment status, early retirement due to MS; frequency of DMTs; 
steroid-drug therapy; and documented off-label applications. Further-
more, the current type of care was evaluated in terms of family care, 
outpatient care, day care, short-term care, and full inpatient care. The 
required medical aids under assessment were walking aids, tub aids, 
wheelchairs, and rollators. The area of physiotherapy was analysed both 
in general terms and according to symptoms. 
The statistical analyses included descriptive statistics including 95% 
confidence intervals for metric and categorical outcomes. Generalised 
additive models were used to investigate MRI frequencies and risk fac-
tors for low assessment rates as a function of age, disease duration, or 
calendar time. Estimated MRI coverages are visualized by contour plots. 
Due to the exploratory nature of the study, no adjustment for multiple 
testing was made and the analyses were performed at a confidence level 
of 95%. The data transformation, statistical analyses, and figure creation 
were performed using R 4.0.2 (R Foundation for Statistical Computing, 
Vienna, Austria, packages: mgcv_1.8-31, nlme_3.1-148, ms.sev_1.0.4, 
compareGroups_4.4.1). 
The GMSR was registered with the German Register of Clinical 
Studies (DRKS, Deutsches Register Klinischer Studien, DRKS; No. 
DRKS00011257). Initial ethical approval was obtained from the insti-
tutional review board at the University of Würzburg. Anonymised data 
will be made available on request for any qualified investigator under 
the terms of the registries’ usage and access guidelines and subject to the 
informed consent of the patients. 
3. Results 
We identified 4,263 SPMS patients with last recorded visit in the 
GMSR after January 2016. The details of the patients in the different 
subgroups are shown in Fig. 1. 
Out of the total sample of 4,263 SPMS patients, 1,513 (35.5%) could 
be classified as either ‘active’ or ‘inactive’ MS, while 2,750 (64.5%) were 
‘unclassifiable’ due to missing MRI data and the absence of relapses (the 
latter alone did not allow for the categorisation of ‘inactive’ since the 
absence of relapse does not mean the absence of subclinical [MRI] 
activity). 
Out of the 1,513 SPMS patients with the required data available, 467 
were classified as ‘active SPMS’ (30.9%) and 1,046 as ‘inactive SPMS’ 
(69.1%). 
3.1. Persistence of activity classifications 
A comparison of the classifiability of the patients according to the 
one-year criteria and the five-year criteria is presented in the Supple-
mentary Fig. 1. \Fig. 2 shows a plot of the actual time (x-axis) since the 
last visit (occurrence of all relapses and MRI) as well as the (temporal) 
certainty of the classification (y-axis). This Fig. can also be read much 
like a (time)-reversed survival curve related to the delay of updated 
information for the subgroups due to the chronological order of the 
disease activity classification. The number of classifiable patients could 
be increased by 20% (83.0%− 1, see Fig. 2) in the inactive patient group 
and by 34% (74.6%− 1) in the active patient group when using a five-year 
window instead of the one-year window. 
3.2. Frequency of MRI measures 
As shown in Fig. 1, the classification as active SPMS was most 
frequently conducted considering recently acquired MRI data. The 
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presence of relapses indicates active disease; however, only 223 of the 
analysed SPMS patients (5.2%) experienced relapses within the year 
before their last visit. MRI data were available for 1,414 SPMS patients 
(33.2%), which allowed for a more comprehensive classification. 
However, the relatively low rate of MRI measures in this population 
raised questions regarding how often MRI is carried out in actual clinical 
practice for SPMS patients in Germany and whether either age or disease 
duration influence the frequency. Therefore, we analysed the MRI pro-
portions per visit in terms of age and disease duration, with the results of 
a generalised additive regression model shown in Fig. 3. 
In our SPMS cohort, a younger age and a shorter disease duration 
were both associated with more frequently reported MRI. The MRI rate 
(at last visit) in the SPMS patients with a short disease duration (≤10 
years) was above 30%, while the patients suffering from MS for over 
>50 years generally had an MRI rate of below 20%. Furthermore, the 
MRI rate in the patients aged ≤40 years was around 40%, while the 
frequency in patients aged ≥70 years fell below 25% per visit. Effect 
sizes for age (odds ratio (OR) per 10 years: 1.22, 95% confidence in-
terval: [1.12, 1.33], p < 0.001) and for disease duration (OR per 10 years 
1.19 [1.09, 1.30], p < 0.001) were of similar extent. 
3.3. Demographics, baseline disease characteristics, and current DMT use 
In the next step of our analysis, we compared the demographic and 
baseline disease characteristics in terms of three patient subgroups 
(active SPMS, inactive SPMS, and unclassifiable). No significant differ-
ences were found between the patients with active SPMS and those with 
inactive SPMS with regard to sociodemographic and clinical 
characteristics (p ≥ 0.26), see Table 1. However, the unclassifiable pa-
tients had a similar mean age at onset but a higher mean disease dura-
tion and were thus significantly older than the population in the 
classifiable groups. 
The DMT rate in the unclassifiable group (43%) was significantly 
lower than in the classifiable groups (active: 56%, inactive: 57%). 
Detailed medication data were available for a subset of 113 active SPMS 
patients, 244 inactive SPMS patients, and 409 unclassifiable SPMS pa-
tients. With regard to the frequency of the use of single DMTs and steroid 
therapies (high-dosage pulse therapy, intrathecal steroids, or long-term 
therapy), no significant differences were found between the patients 
with active SPMS and those with inactive SPMS except a slight one in 
natalizumab (Table 1). 
3.4. Frequency of symptoms, disability status, and healthcare utilization 
As shown in Supplementary Table 1, SPMS patients with an active 
disease were slightly more likely to experience visual disturbances or 
blurred vision at MS onset (47% vs. 40%, p = 0.025 [Fisher exact test]), 
bladder dysfunction (19% vs. 13%, p = 0.016), and bowel dysfunction 
(8% vs. 3%, p = 0.001) in comparison to those with an inactive disease. 
No significant differences were found between the groups in terms of 
motor symptoms (weakness, paralysis), cerebellar disorders (coordina-
tion, fine motor disturbance, tremor ataxia), sensory disturbances 
(misperceptions, emotional disorders of different qualities), sexual dis-
orders, brain stem function disorders (double vision, facial sensation, 
facial paralysis, hearing loss, speech disorder, dysphagia), depression, 
euphoria, concentration and/or memory disorders, or polysymptomatic 
Fig. 1. Flowchart of all 4,263 SPMS patients. The MRI results and the occurrence of relapses were evaluated either at or within the year before the last visit of each 
PwMS (Supplementary Fig. 1 shows the extension to five years). MRI, magnetic resonance imaging; n, number of patients; PwMS, patient with multiple sclerosis; 
SPMS, secondary progressive multiple sclerosis. 
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onset and other onset symptoms. In terms of current symptoms, the 
active SPMS patients experienced a greater frequency of pain (46% vs. 
40%, p = 0.032), cognitive dysfunction (45% vs. 36%, p = 0.002), and 
depression (33% vs. 28%, p = 0.050), while the inactive SPMS patients 
suffered more frequently from fatigue (60% vs. 66%, p = 0.019). There 
was no significant difference between the groups in terms of frequencies 
of spasticity, ataxia, micturition disturbances, defecation disturbances, 
sexual disorders, oculomotor disturbances, dysarthria, dysphonia, 
dysphagia, epileptic seizures, walking problems, and other paroxysms. 
Furthermore, in the year prior to the last visit, the active SPMS patients 
used wheelchairs more often (57% vs. 52%, p = 0.045) and required 
inpatient care more often (4% vs. 1%, p = 0.008) than the inactive SPMS 
patients. No significant differences were found in terms of disability 
(EDSS, MSSS), physiotherapy, or employment status between the two 
groups. When comparing the classifiable and unclassifiable patients, the 
latter had, besides higher disease duration, significantly higher EDSS 
Fig. 2. Scatterplot showing the delay of relapses and/or MRI for classification since the last visit (SPMS patients, n=4,263). Occurrence of relapses and (updated) 
MRI visits are displayed for each patient as a horizontal timeline. The patients’ timelines are thereby ordered vertically (y-axis) by the date of latest classifiability, 
with patients more recently rated as active towards the bottom and patients more recently rated as inactive towards the top. The subgroups were of different sizes and 
their total numbers are given. The x-axis shows the time since the patient’s last visit up to 5 years. MRI with stable results is shown by the green circles, MRI with 
active results by the red triangles and relapses by the purple crosses. When using the (fixed) one-year window the classifiability of patients were 74.6% (active) or 
83.0% (inactive) in relation to a five years extension. MRI, magnetic resonance imaging; n, number of patients; SPMS, secondary progressive multiple sclerosis. 
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scores, required more frequent outpatient care, and used a wheelchair 
more often. 
4. Discussion 
In this multicentre cohort study, a classification of SPMS patients was 
performed based on disease activity. The aims of the present investi-
gation were to estimate the frequency of ‘active’ and ‘inactive’ SPMS and 
to identify the differences in terms of sociodemographic and clinical 
data, symptomatology, and healthcare utilisation between the two 
subgroups, based on real-world data. 
The secondary progressive course of MS is both a diagnostic and a 
therapeutic challenge. On the one hand, the conversion of RRMS into 
SPMS is not clearly delineated because the transition phase runs 
smoothly without a clearly defined time point (Filippi et al., 2018; 
Giovannoni et al., 2016; Tremlett et al., 2008), while on the other hand, 
DMTs have largely been studied in patients with RRMS, meaning the 
immunotherapeutic options of SPMS with adequate efficacy are limited 
(Bhatia and Singh, 2019; Dargahi et al., 2017; Kappos et al., 2018). 
While Siponimod was the first drug specifically licensed for SPMS, its 
approval is limited to MS patients with an active disease (i.e. those with 
superimposed relapses and/or MRI activity) (European Medicines 
Agency, 2019). Meanwhile, interferon beta, cladribine, and ocrelizumab 
may also be used in patients with SPMS who exhibit clinical activity 
(relapsing MS, RMS), which means its use is, again, limited to MS pa-
tients with active SPMS. Treatments that effectively inhibit the contin-
uous disability progression in SPMS patients in addition to reducing 
relapse activity would be long-awaited improvement in the therapy of 
SPMS patients. 
One of our main findings was that according to the definition 
adapted from Lublin et al., 2014 only around one third of our SPMS 
patients could be classified as active, which indicates that there may still 
exist actual shortcomings in the classification of disease activity. Our 
results demonstrated that elderly patients with long disease durations 
are particularly less-frequently monitored via MRI, which may be 
associated with the small number of immunotherapeutic options for 
SPMS patients of an advanced age. Similar results regarding the fre-
quency of MRI during the past year were found in Sweden, with a 
notable decrease with higher age and disease duration (Swedish MS 
registry, 2020). Furthermore, MRI capacities are subject to strong 
regional differences. However, regularly performed MRI plays an 
important role in the evaluation of disease activity (as shown both in our 
study and in others (Kaunzner et al., 2017)), since the relapse rate in 
progressing SPMS is generally low (Ontaneda, 2019). This finding was 
confirmed in our study, with only around 5% of our 4,263 patients 
experiencing relapses in the year prior to the evaluated medical exam-
ination. Regular monitoring and standardised MRI follow-up examina-
tions (Rovira et al., 2015; Wattjes et al., 2015), especially at an advanced 
age, would provide new data and allow for a more appropriate and 
accurate identification of active SPMS patients. 
It is worth noting that ‘MRI activity’ (new T2 lesions) in patients aged 
over 55–60 is likely to be confounded by lesions that are not MS- 
associated but are due to the increasing number of comorbidities 
(especially cerebrovascular) in elderly populations (e.g. hypertension) 
(Filippi et al., 2020; Guisset et al., 2020). Insufficient reproducibility of 
longitudinal MRI findings (especially beyond approval studies) has long 
been known as a problem in MRI follow-up investigations among clinical 
neurologists (Molyneux et al., 1999). Even relapses may lack discrimi-
nation from non-MS pathologies with increasing age. MRI data or 
relapse activity alone may thus have shortcomings in sensitivity as well 
Fig. 3. Proportions of updated MRIs depending on age and disease duration. For the last recorded visit per SPMS patient, the orange and yellow areas indicate that 
more than 30% of visits were associated with an updated MRI status, while the green areas indicate rates of less than 30%. The light purple points indicate a visit with 
updated MRI information, while the dark brown points indicate visits without updated MRI information. MRI, magnetic resonance imaging. 
N. Frahm et al.                                                                                                                                                                                                                                  
Multiple Sclerosis and Related Disorders 56 (2021) 103281
6
as in specificity for the classification of patients into active and inactive 
SPMS groups. 
In summary, only marginal differences in the onset and current 
symptoms between the active and inactive SPMS groups were found and 
both groups are rather homogeneous. In terms of care and aids, wheel-
chair use was slightly more frequent among the ‘active’ SPMS patients 
than the ‘inactive’ patients (57% vs. 52%). This difference could be due 
to a temporary gait impairment related to relapses (Cameron and Nil-
sagard, 2018). This aside, the required aid did not depend as much on 
the disease activity as on age and disease duration. Overall, the lack of 
correlation with the evaluated demographic, symptomatic and status of 
care covariates is to be expected, as this suggests that MRI activity may 
provide an independent component of information which may not be 
available through these easy-access types of data. 
The DMTs were only reported at a descriptive level since the activity 
of the disease and the treatment are co-dependent. In short, it was not 
clear whether disease activity triggered a change in the DMT or whether 
the administered DMT ensured that the disease remained inactive. Here, 
analyses using marginal structural models similar to those used by 
Spelman et al. (2020) for a given SPMS cohort would be of interest and 
could form the basis of follow-up research. In our study, ocrelizumab, 
interferon beta, and mitoxantrone were the most commonly used DMTs 
among both the active and inactive patients as well as those who could 
not be classified. These parallels in therapeutic strategies were likely due 
to the limited number of approved SPMS drugs (Dargahi et al., 2017; 
Kappos et al., 2018) and the fact that the licensure of cladribine and 
siponimod occurred during or after the observation period for our 
analysis. Considering the relatively high average age of 55 years, the 
disease duration of more than 20 years and the relatively high disability 
level, the DMT rate of more than 50% seems rather ambitious, especially 
when taking into account the fact that the clinical effectiveness of 
high-efficacy DMTs and low-efficacy DMTs does not differ in MS patients 
older than 40 years (Weideman et al., 2017). Nevertheless, targeted 
inclusion of older MS patients in DMT clinical trials is useful to inves-
tigate the effect of immune senescence and the possible accumulation of 
side effects (Papadopoulos et al., 2020; Vaughn et al., 2019). To date, 
study populations of clinical trials cannot be compared with real-world 
patient cohorts. Specific inclusion criteria of clinical trials, especially 
with respect to age, disease activity, and drug regimen, do not reflect the 
broad majority of MS patients (Jalusic et al., 2021). 
One limitation of this study is that only 35.5% of our 4,263 SPMS 
patients could be classified as active or inactive. This low classification 
rate was largely due to the lack of MRI data, especially for older MS 
patients or for those with a longer disease duration, as was discussed in 
detail above. As such, the current registered number of SPMS patients 
with disease activity may have been underestimated. The selection of 
the time interval for classifying the disease activity in SPMS patients was 
a topic that had to be investigated separately. Here, with reference to 
Lublin et al. (2014), we used an interval of one year as the regular time 
frame; however, other periods can be considered suitable in certain 
situations. To experiment with a longer period, we looked at a larger 
time frame of up to five years. More patients could be reclassified but the 
data wasn’t suggesting that an even five-year period will solve the 
mentioned shortcomings. Considering a one-year period seems thus 
reasonable. Nevertheless, our data suggest that too many patients do not 
receive regular MRI at all, as a real-world matter. In addition, there is the 
possibility of the under-reporting of SPMS, since the physicians may 
have avoided changing the diagnosis from RRMS to SPMS due to the lack 
of treatment options. 
In conclusion, this paper provides an overview of the frequency and 
characteristics of SPMS patients according to disease activity. Today, 
MRI data play an important role in the classification of disease activity 
into ‘active’ and ‘inactive’. However, despite this, the MRI rate tends to 
decline with an increase in age and longer disease durations. 
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